Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if the drug lopinavir/ritonavir (LPV/RTV) is safe
and well tolerated in HIV infected infants. This study will also determine the most effective
dose of LPV/RTV for infants.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)